Inscripta

The company's core business revolves around providing tools that empower scientists to engineer microbes for biomanufacturing, aiming to create sustainable alternatives to traditional manufacturing processes. Inscripta targets researchers and scientists in academic institutions, as well as commercial entities in sectors like industrial chemicals, healthcare, and agriculture. Its business model centers on the sale of its integrated platform, consumables, and software, which together streamline the complex process of genome editing.

Inscripta's primary offering is the Onyx® platform, a comprehensive solution for digital genome engineering. This platform automates the engineering of microbial genomes, allowing scientists to generate and test vast libraries of genetic edits simultaneously. The key components include proprietary gene-editing enzymes (MADzymes), engineered cells, intuitive software for designing experiments, and the benchtop instrument itself. This high-throughput capability accelerates the design-build-test cycle, enabling researchers to more rapidly develop microbes for producing novel enzymes, therapeutic proteins, or sustainable chemicals. A significant milestone for the company was raising over $150 million in a Series D financing round, which has supported the commercial expansion of the Onyx platform. The company maintains operations in Pleasanton and Burlingame, California, serving a global customer base.